Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions

Biochemical and Biophysical Research Communications

Volumn 467, Issue 4, 2015, Pages 948-954

  Shimo, Naoki ^a   Matsuoka, Taka Aki ^a   Miyatsuka, Takeshi ^a,b   Takebe, Satomi ^a   Tochino, Yoshihiro ^a   Takahara, Mitsuyoshi ^a   Kaneto, Hideaki ^c   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Fibrate; Glucotoxicity; Insulin transcription factors; islet cell dysfunction; Lipotoxicity; SGLT2 inhibitor

Indexed keywords

BEZAFIBRATE; EMPAGLIFLOZIN; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER 2; GLUTATHIONE PEROXIDASE 1; GLYCOSYLATED ALBUMIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HSPA5 PROTEIN; INSULIN; INSULIN 1; INSULIN 2; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MESSENGER RNA; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR PDX 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; GLYCEMIC CONTROL; INSULIN SYNTHESIS; LIPOTOXICITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PANCREAS ISLET;

ANIMALS; APOPTOSIS; BENZHYDRYL COMPOUNDS; BEZAFIBRATE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GLUCOSE; GLUCOSIDES; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; LIPIDS; MICE;

EID: 84946599933     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.10.038     Document Type: Article

References (26)

1. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group Diabetes 44 1995 1249 1258
2. J. Levy, A.B. Atkinson, P.M. Bell, and et al. β-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the belfast diet study Diabet. Med. 15 1998 290 296
3. S.E. Kahn, S.M. Haffner, M.A. Heise, and et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N. Engl. J. Med. 355 2006 2427 2443
4. S. Bonner-Weir, D.F. Trent, and G.C. Weir Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release J. Clin. Invest. 71 1983 1544 1553
5. R.P. Robertson, H.J. Zhang, K.L. Pyzdrowski, and et al. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations J. Clin. Invest. 90 1992 320 325
6. M.L. Elks Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release Endocrinology 133 1993 208 214
7. T.M. Mason, T. Goh, V. Tchipashvili, and et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats Diabetes 48 1999 524 530
8. T.A. Matsuoka, H. Kaneto, S. Kawashima, and et al. Preserving Mafa expression in diabetic Islet β-cells improves glycemic control in vivo J. Biol. Chem. 290 2015 7647 7657
9. J.C. Jonas, A. Sharma, W. Hasenkamp, and et al. Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes J. Biol. Chem. 274 1999 14112 14121
10. D.R. Laybutt, M. Glandt, G. Xu, and et al. Critical reduction in β-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes J. Biol. Chem. 278 2003 2997 3005
11. C. Kjorholt, M.C. Akerfeldt, T.J. Biden, and et al. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of β-cell differentiation and secretory function in the db/db mouse model of diabetes Diabetes 54 2005 2755 2763
12. S. Kawashima, T.A. Matsuoka, H. Kaneto, and et al. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice Biochem. Biophys. Res. Commun. 404 2011 534 540
13. A. Pick, J. Clark, C. Kubstrup, and et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat Diabetes 47 1998 358 364
14. M.Y. Donath, D.J. Gross, E. Cerasi, and et al. Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes Diabetes 48 1999 738 744
15. K. Maedler, J. Oberholzer, P. Bucher, and et al. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic β-cell turnover and function Diabetes 52 2003 726 733
16. L. Chen, T. Klein, and P.S. Leung Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice Curr. Mol. Med. 12 2012 995 1004
17. J. Chen, S. Williams, S. Ho, and et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members Diabetes Ther. 1 2010 57 92
18. J.S. Harmon, C.E. Gleason, Y. Tanaka, and et al. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats Diabetes 50 2001 2481 2486
19. H. Wang, T. Brun, K. Kataoka, and et al. MAFA controls genes implicated in insulin biosynthesis and secretion Diabetologia 50 2007 348 358
20. G. Waeber, N. Thompson, P. Nicod, and et al. Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor Mol. Endocrinol. 10 1996 1327 1334
21. M. Takahara, T. Shiraiwa, T.A. Matsuoka, and et al. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin Endocr. J. 62 2015 77 86
22. M.J. Jurczak, H.Y. Lee, A.L. Birkenfeld, and et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function Diabetes 60 2011 890 898
23. Y. Fujimori, K. Katsuno, I. Nakashima, and et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J. Pharmacol. Exp. Ther. 327 2008 268 276
24. E. Ferrannini, L. Seman, E. Seewaldt-Becker, and et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes. Obes. Metab. 15 2013 721 728
25. M. Guerre-Millo, P. Gervois, E. Raspe, and et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity J. Biol. Chem. 275 2000 16638 16642
26. S. Ogawa, K. Takeuchi, K. Sugimura, and et al. Bezafibrate reduces blood glucose in type 2 diabetes mellitus Metabolism 49 2000 331 334